news Small molecule RGX-202 prevents metastasis in colorectal cancer 7 October 2021 | By Anna Begley (Drug Target Review) RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
news Novel “living medicine” could treat antibiotic-resistant infections 6 October 2021 | By Anna Begley (Drug Target Review) Researchers have created the first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.
news UC Riverside granted $5 million for stem cell research training 6 October 2021 | By Anna Begley (Drug Target Review) A $5 million grant will be used to train students in stem cell research to contribute towards new stem cell-based therapeutics.
news Two-week-old human embryos reveal origin of Huntington’s disease 6 October 2021 | By Anna Begley (Drug Target Review) Scientists have discovered a signalling pathway alteration in embryos with Huntington’s disease, paving the way for ground-breaking treatments.
news Psilera to collaborate with NIDA on pre-clinical psychedelic studies 5 October 2021 | By Anna Begley (Drug Target Review) Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
news Gene therapy method could restore visual function after stroke 4 October 2021 | By Anna Begley (Drug Target Review) Scientists have revealed a way to use gene therapy to turn glial brain cells into neurons, restoring vision and potentially restoring motor function.
news Utilising aquaporins could be the key to repairing corneal defects 1 October 2021 | By Anna Begley (Drug Target Review) New evidence suggests that aquaporin 5 (Aqp5) induction promotes corneal epithelial regeneration, which could lead to possible therapies.
news Zaki syndrome: the newly uncovered condition and its potential cure 1 October 2021 | By Anna Begley (Drug Target Review) Dubbed 'Zaki syndrome', the condition affects prenatal development of several organs and was identified using whole genome sequencing.
video Discussing next-gen AAV vectors with Dr Arun Srivastava, University of Florida 30 September 2021 | By Drug Target Review An interview with Dr Arun Srivastava about his research into safe and effective AAV vectors that do not prompt a reaction from the immune system.
news CRISPR screening tool exposes new leukaemia drug target 29 September 2021 | By Anna Begley (Drug Target Review) A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
news NINDS awards Sinopia $3.3m for development of Parkinson’s drug candidate 29 September 2021 | By Anna Begley (Drug Target Review) Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
news “Ultrasensitive” HPV detection paves way for precision treatment 28 September 2021 | By Anna Begley (Drug Target Review) A new study sequenced tumour DNA for the “ultrasensitive” detection of HPV, further honing precision treatment of the illness.
news Promising pre-clinical data announced for Parkinson’s drug 27 September 2021 | By Anna Begley (Drug Target Review) Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
news New AI technology could shape the future of RNA therapeutics 27 September 2021 | By Anna Begley (Drug Target Review) Artificial intelligence was shown to predict the 3D shapes of RNA molecules, which could significantly advance RNA therapeutics.
news Ground-breaking small molecule attenuates neuroinflammation in mice 27 September 2021 | By Anna Begley (Drug Target Review) Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
